This article discusses clinical data for noncovalent Bruton tyrosine kinase inhibitors (BTKis), novel strategies in CLL, and the practical management of BTKi toxicities.
Yuxi Lei, PharmD
Advertisement
Articles by Yuxi Lei, PharmD
This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.
Integrating immunotherapies will continue to improve patient outcomes and quality of life.
Advertisement
Latest Updated Articles
Recent Clinical Trials Reveal Important Updates in Adjuvant Therapy for Resectable Non–Small Cell Lung CancerPublished: October 20th 2023 | Updated:
Chronic Lymphocytic Leukemia: A Review of Noncovalent BTK Inhibitors, Novel Agents, and Toxicity Management of BTK InhibitorsPublished: August 19th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
2
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
3
Weekly Paclitaxel May Hold the Key to Pembrolizumab’s Success in Platinum-Resistance Ovarian Cancer
4
Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer
5
